MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of MaxCyte stock in a transaction on Monday, August 26th. The shares were sold at an average price of $4.28, for a total transaction of $12,840.00. Following the completion of the transaction, the director now directly owns 141,950 shares of the company’s stock, valued at approximately $607,546. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

John Joseph Johnston also recently made the following trade(s):

• On Friday, July 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The shares were sold at an average price of $4.75, for a total value of $14,250.00.
• On Thursday, June 27th, John Joseph Johnston sold 10,000 shares of MaxCyte stock. The stock was sold at an average price of $3.99, for a total value of $39,900.00.

MaxCyte Price Performance

Shares of MaxCyte stock remained flat at $4.24 during trading hours on Wednesday. 430,047 shares of the stock were exchanged, compared to its average volume of 557,764. The firm has a 50-day moving average price of $4.28 and a two-hundred day moving average price of $4.34. The stock has a market capitalization of $444.45 million, a P/E ratio of -12.11 and a beta of 1.42. MaxCyte, Inc. has a fifty-two week low of $2.45 and a fifty-two week high of $5.55.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.68% and a negative net margin of 83.00%. The business had revenue of $10.43 million for the quarter, compared to analyst estimates of $8.20 million. During the same quarter in the previous year, the firm earned ($0.10) EPS. As a group, research analysts anticipate that MaxCyte, Inc. will post -0.5 EPS for the current fiscal year.

Institutional Trading of MaxCyte

Several institutional investors and hedge funds have recently bought and sold shares of MXCT. Victory Capital Management Inc. lifted its stake in MaxCyte by 23.0% during the fourth quarter. Victory Capital Management Inc. now owns 12,316 shares of the company’s stock worth $58,000 after purchasing an additional 2,306 shares in the last quarter. AJOVista LLC acquired a new stake in shares of MaxCyte in the fourth quarter valued at $70,000. River Global Investors LLP grew its position in shares of MaxCyte by 3.1% during the fourth quarter. River Global Investors LLP now owns 1,518,646 shares of the company’s stock worth $7,053,000 after buying an additional 45,392 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of MaxCyte by 29.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 2,537,114 shares of the company’s stock valued at $11,924,000 after purchasing an additional 584,372 shares in the last quarter. Finally, Roubaix Capital LLC purchased a new stake in shares of MaxCyte during the 4th quarter worth $1,815,000. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.